Integra LifeSciences provides update plans for manufacturing facility in MA

Integra LifeSciences is announcing its plans to restart the manufacture of PriMatrix and SurgiMend at its new manufacturing facility in Braintree, Massachusetts, MA. The Company expects to operationalize this new facility in the first half of 2026. Since receiving the third-party audit findings for its Boston, Massachusetts, manufacturing facility in March, the Company has been thoroughly reassessing its plans and timeline to resume the manufacture of PriMatrix and SurgiMend at this site. In parallel, the Company has been furthering its plans to complete the construction and operationalization of its new state-of-the-art tissue manufacturing facility in Braintree. “Given the advantages of the Braintree facility and the challenges of the Boston facility, the decision to consolidate our efforts at our new Braintree location enables us to focus our resources in one location. This represents a minimal difference in timing compared to restarting in our existing Boston facility, while limiting execution risk,” said Robert Davis, Jr., executive vice president and president of Integra’s Tissue Technologies division.